SCHEMBL30639062

SCHEMBL30639062

CC(C)(C)OC(=O)N1CCN(C(=O)c2ccc3c(c2)C(=O)c2nc4cc(Cl)cc(Cl)c4c(=O)n2-3)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.50
▸ TDO2 P48775 1/20 0.50
▸ IDO2 Q6ZQW0 1/20 0.50
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ POLB P06746 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ APAF1 O14727 1/20 0.39
▸ CASP1 P29466 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ GPR119 Q8TDV5 2/20 0.39
▸ AKT1 P31749 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ CRBN Q96SW2 1/20 0.38
▸ CNR2 P34972 2/20 0.38
▸ CNR1 P21554 1/20 0.38
▸ LMNA P02545 3/20 0.37
▸ KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26614087 1.00 IDO1 (0.50) IDO1TDO2IDO2MEN1KMT2A
SCHEMBL30639089 0.87 IDO1 (0.55) IDO1TDO2IDO2MEN1KMT2A
SCHEMBL26614124 0.87 IDO1 (0.55) IDO1TDO2IDO2MEN1KMT2A
SCHEMBL26614297 0.87 APAF1 (0.46) IDO1TDO2IDO2MEN1KMT2A
SCHEMBL26614178 0.84 ADORA2A (0.44) IDO1TDO2IDO2APAF1
SCHEMBL30639084 0.84 ADORA2A (0.44) IDO1TDO2IDO2APAF1
SCHEMBL30639054 0.79 APAF1 (0.39) IDO1TDO2IDO2MEN1KMT2A
SCHEMBL30639058 0.79 APAF1 (0.53) IDO1TDO2IDO2MEN1KMT2A
SCHEMBL26614131 0.79 APAF1 (0.53) IDO1TDO2IDO2MEN1KMT2A
SCHEMBL30639068 0.78 APAF1 (0.47) IDO1TDO2IDO2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. 2025-05-29 — — US disclosed
EP-4514804-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF Viscient Bio, Inc. (US) 2025-03-05 — — EP disclosed
WO-2023211977-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. (US) 2023-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF IDO2, IDO1, TPSB2 IDO1 2/4885TDO2 8/4885IDO2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback